REMARKS

In response to the Notice to File Missing Parts of Nonprovisional Application, Applicants submit herein an initial computer readable form (CRF) copy of the "Sequence Listing," and an initial paper copy of the "Sequence Listing." No new matter has been added. A statement that the content of the paper and computer readable copies are the same and include no new matter, in compliance with 37 C.F.R. §§ 1.821 – 1.825 is also included

The Specification has been amended to insert the sequence listing and to correct reference to sequence identifiers. No new matter has been added.

Applicants believe that no fee is due with the submission of this Amendment. However, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-222 (Cura-522).

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding this submission, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

for: (Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants c/o MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, P.C. One Financial Center

Boston, Massachusetts 02111 Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: October 31, 2002

22.1

APPENDIX A Marked-up Version Showing Changes Made

In the Specification:

On page 165, lines 10-14:

Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an NOVX protein of [SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 29, and 31] <u>SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, and 38, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37, are additionally provided.</u>

Pages 1-289 of sequence listing added.

TRA 1671181v1

4